Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lynn Y. L. Huang"'
Autor:
Sai Fung Chung, Murray Cutler, Lynn Y L Huang, Thomas Wai-hung Lo, Johnson Y.N. Lau, Kuo-Ming Yu, Tammy Pui-shi Pang, Thomas Yun-Chung Leung, Min Tian
Publikováno v:
Life Sciences. 264:118674
Aims Arginine depleting enzymes are found effective to treat arginine-auxotrophic cancers and therapy-resistant malignancies, alone or in combination with cytotoxic agents or immune checkpoint inhibitors. We aim to select and validate a long-lasting,
Autor:
Lynn Y. L. Huang1 lynnhuang.lh245@gmail.com, Ying-Shuan Lee2 yslee@dcb.org.tw, Jiann-Jyh Huang2 lukehuang@mail.ncyu.edu.tw, Chia-chi Chang1 chichang@taivex.com, Jia-Ming Chang2 jiaming@dcb.org.tw, Shih-Hsien Chuang2 Shchuang51@mail.dcb.org.tw, Kuo-Jang Kao1 kuojang.kao@gmail.com, Yung-Jen Tsai2 yungjentsai@dcb.org.tw, Pei-Yi Tsai2 pytsai@dcb.org.tw, Chia-Wei Liu2 chiawei@dcb.org.tw, Her-Sheng Lin2 sheng@dcb.org.tw, Lau, Johnson Y. N.1 JohnsonYNLau@aol.com
Publikováno v:
Journal of Experimental & Clinical Cancer Research (17569966). 2014, Vol. 33 Issue 1, p1-31. 30p.
Autor:
Chia-chi Chang, Jiann-Jyh Huang, Ying-Shuan Lee, Gillian M.G. Lau, Johnson Y.N. Lau, Her-Sheng Lin, Lynn Y L Huang, Robert G. Gish, Kuo-Jang Kao, Jia-Ming Chang, Shih-Hsien Chuang, Chia-Wei Liu, Pei-Yi Tsai
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:511-520
Highly expressed in cancer protein 1 (Hec1) is an oncogene and a promising molecular target for novel anticancer drugs. The purpose of this study was to evaluate the potential of a Hec1 inhibitor, TAI-95, as a treatment for primary liver cancer.In vi
Autor:
Sheng-Chuan Yang, Ying-Shuan E. Lee, Chia-Wei Liu, Johnson Y.N. Lau, Shih-Hsien Chuang, Jun-Yu Lai, Her-Sheng Lin, Jia-Ming Chang, Ju-Ying Yang, Pei-Shiou Jian, Chun-Liang Lai, Yu-Hsiang Lin, Chia-chi Chang, Lynn Y L Huang, King Lam, Jiann-Jyh Huang
Publikováno v:
Journal of Medicinal Chemistry. 57:4098-4110
A series of 4-aryl-N-arylcarbonyl-2-aminothiazoles of scaffold 4 was designed and synthesized as Hec1/Nek2 inhibitors. Structural optimization of 4 led to compound 32 bearing C-4' 4-methoxyphenoxy and 4-(o-fluoropyridyl)carbonyl groups that showed lo
Autor:
Chia-Wei Liu, Jia-Ming Chang, Jiann-Jyh Huang, Lynn Y L Huang, Shih-Hsien Chuang, Chia-chi Chang, Johnson Y.N. Lau, Pei-Yi Tsai, Kuo-Jang Kao, Her-Sheng Lin, Ying-Shuan Lee, Gillian M.G. Lau
Publikováno v:
Molecular cancer therapeutics. 13(6)
Current cytotoxic chemotherapy produces clinical benefit in patients with breast cancer but the survival impact is modest. To explore novel cytotoxic agents for the treatment of advanced disease, we have characterized a new and pharmacokinetically im
Autor:
Jiann-Jyh Huang, Jia-Ming Chang, Her-Sheng Lin, Yung-Jen Tsai, Pei-Yi Tsai, Ying-Shuan Lee, Chia-Wei Liu, Chia-chi Chang, Kuo-Jang Kao, Shih-Hsien Chuang, Lynn Y L Huang, Johnson Y.N. Lau
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Background Hec1 (NDC80) is an integral part of the kinetochore and is overexpressed in a variety of human cancers, making it an attractive molecular target for the design of novel anticancer therapeutics. A highly potent first-in-class compound targe
Autor:
Jiann-Jyh Huang, Paonien Chen, Yung-Jen Tsai, Johnson Y.N. Lau, Shih-Hsien Chuang, Lynn Y L Huang, Chia-chi Chang, Ying-Shuan Lee, Robert G. Gish
Publikováno v:
Gastroenterology. 142:S-978